Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where N.B. Delongchamps is active.

Publication


Featured researches published by N.B. Delongchamps.


Progres En Urologie | 2012

Bilan initial, suivi et traitement des troubles mictionnels en rapport avec hyperplasie bénigne de prostate : recommandations du CTMH de l’AFU

Aurélien Descazeaud; G. Robert; N.B. Delongchamps; J.-N. Cornu; C. Saussine; O. Haillot; Marian Devonec; M. Fourmarier; Charles Ballereau; Bertrand Lukacs; O. Dumonceau; A.R. Azzouzi; A. Faix; F. Desgrandchamps; A. De La Taille

AIMnTo elaborate guidelines for the diagnosis, the follow-up, and the treatment of benign prostatic hyperplasia (BPH).nnnMETHODnA systematic review of the literature was conducted to select more relevant publications. The level of evidence was evaluated. Graded recommendations were written by a working group, and then reviewed by a reviewer group according to the formalized consensus technique.nnnRESULTSnTerminology of the International Continence Society was used. Initial assessment has several aims: making sure that lower urinary tract symptoms (LUTS) are related to BPH, assessing bother related to LUTS and checking for a possible complicated bladder outlet obstruction (BOO). Initial assessment should include: medical history, LUTS assessment using a symptomatic score, physical examination including digital rectal examination, urinalysis, flow rate recording, and residual urine volume. Frequency volume chart is recommended when storage symptoms are predominant. Serum PSA should be done when the diagnosis of prostate cancer can modify the management. When a surgical treatment is discussed, serum PSA, serum creatinine and ultrasonography of the urinary tract are recommended. BPH patients should be informed of the benign and possibly progressive patterns of the disease. When LUTS cause no bother, annual follow-up should be planned. Medical treatment includes some phytotherapy agents, alpha-blockers and 5-alpha reductase inhibitors. The last two can be associated. The association of antimuscarinics and alpha-blockers can be offered to patients with residual storage symptoms when already under alpha-blockers therapy, after checking for the absence of severe BOO (residual volume more than 200mL or max urinary flow less than 10mL/s). Phosphodiesterase-5 inhibitors could be used in patients complaining for both LUTS and erectile dysfunction. In case of complication, or when medical treatment is inefficient or not tolerated, then a surgical treatment should be discussed. Treatment decision should be done according to type of LUTS and related bother, prostate anatomy, level of obstruction and its consequences on urinary tract, patient co-morbidities, experience of practitioner, and choice of patient. Surgical treatments with the higher level of evidence of efficacy include monopolar or bipolar transurethral resection of the prostate, open prostatectomy, transurethral incision of the prostate, photoselective vaporization of the prostate, and Holmium laser enuclation of the prostate.nnnCONCLUSIONnHere are the first guidelines of the French Urological Association for the initial assessment, the follow-up and the treatment of urinary disorders related to BPH.


Progres En Urologie | 2012

RecommandationBilan initial, suivi et traitement des troubles mictionnels en rapport avec hyperplasie bénigne de prostate : recommandations du CTMH de l’AFUInitial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: Guidelines of the LUTS committee of the French Urological Association

A. Descazeaud; G. Robert; N.B. Delongchamps; J.-N. Cornu; C. Saussine; O. Haillot; Marian Devonec; M. Fourmarier; Charles Ballereau; Bertrand Lukacs; O. Dumonceau; A.R. Azzouzi; A. Faix; F. Desgrandchamps; A. De La Taille

AIMnTo elaborate guidelines for the diagnosis, the follow-up, and the treatment of benign prostatic hyperplasia (BPH).nnnMETHODnA systematic review of the literature was conducted to select more relevant publications. The level of evidence was evaluated. Graded recommendations were written by a working group, and then reviewed by a reviewer group according to the formalized consensus technique.nnnRESULTSnTerminology of the International Continence Society was used. Initial assessment has several aims: making sure that lower urinary tract symptoms (LUTS) are related to BPH, assessing bother related to LUTS and checking for a possible complicated bladder outlet obstruction (BOO). Initial assessment should include: medical history, LUTS assessment using a symptomatic score, physical examination including digital rectal examination, urinalysis, flow rate recording, and residual urine volume. Frequency volume chart is recommended when storage symptoms are predominant. Serum PSA should be done when the diagnosis of prostate cancer can modify the management. When a surgical treatment is discussed, serum PSA, serum creatinine and ultrasonography of the urinary tract are recommended. BPH patients should be informed of the benign and possibly progressive patterns of the disease. When LUTS cause no bother, annual follow-up should be planned. Medical treatment includes some phytotherapy agents, alpha-blockers and 5-alpha reductase inhibitors. The last two can be associated. The association of antimuscarinics and alpha-blockers can be offered to patients with residual storage symptoms when already under alpha-blockers therapy, after checking for the absence of severe BOO (residual volume more than 200mL or max urinary flow less than 10mL/s). Phosphodiesterase-5 inhibitors could be used in patients complaining for both LUTS and erectile dysfunction. In case of complication, or when medical treatment is inefficient or not tolerated, then a surgical treatment should be discussed. Treatment decision should be done according to type of LUTS and related bother, prostate anatomy, level of obstruction and its consequences on urinary tract, patient co-morbidities, experience of practitioner, and choice of patient. Surgical treatments with the higher level of evidence of efficacy include monopolar or bipolar transurethral resection of the prostate, open prostatectomy, transurethral incision of the prostate, photoselective vaporization of the prostate, and Holmium laser enuclation of the prostate.nnnCONCLUSIONnHere are the first guidelines of the French Urological Association for the initial assessment, the follow-up and the treatment of urinary disorders related to BPH.


Progres En Urologie | 2012

Bilan initial et suivi de l’hyperplasie bénigne de prostate : revue de littérature du CTMH de l’AFU

Aurélien Descazeaud; G. Robert; N.B. Delongchamps; J.-N. Cornu; C. Saussine; O. Haillot; Marian Devonec; M. Fourmarier; Charles Ballereau; Bertrand Lukacs; O. Dumonceau; A.R. Azzouzi; A. De La Taille

PURPOSEnTo perform an update on the initial evaluation and follow-up of benign prostatic hyperplasia (BPH).nnnMETHODnA systematic review of recent literature was performed. Level of evidence of publications was evaluated.nnnRESULTS AND CONCLUSIONSnObjectives of the initial evaluation are to assess the link between low urinary tract symptoms (LUTS) and BPH, to evaluate the bother associated to LUTS, assess a complicated bladder outlet obstruction (BOO), diagnose an adenocarcinoma of the prostate if it modifies the therapeutic strategy, and establish an evolutive profile of the disease. Clinical assessment with digital rectal examination, evaluation of symptoms by a dedicated questionnaire and urine analysis are the first steps of BPH evaluation. Bladder diary is useful to objective storage symptoms. Uroflowmetry and post-void residual volume assessment are useful if BOO is suspected. Measure of serum creatinine and ultrasound exam of the urinary tract are second line explorations. Urine cytology, neurological evaluation, urethrocystoscopy, urodynamics with pressure-flow studies are useful if the link between LUTS and BPH is unclear. PSA dosage is used for prostate cancer screening or as a prognostic marker of BPH evolution.


Urologia Internationalis | 2010

Impact of Lower Urinary Tract Symptoms on Discomfort in Men Aged between 50 and 80 Years

Grégoire Robert; Aurélien Descazeaud; Rahmene Azzouzi; Christian Saussine; O. Haillot; O. Dumonceau; Charles Ballereau; Marc Fourmarier; Marian Devonec; Bertrand Lukacs; N.B. Delongchamps; François Desgrandchamps; Alexandre de la Taille

Background/Aims: There are only a few surveys on the prevalence of lower urinary tract symptoms (LUTS) among the general population. The aim of this survey was to assess the prevalence of LUTS and their impact on discomfort in men. Methods: A questionnaire was mailed to 3,877 men aged 50–80 years, which included questions on their medical history, demographic and sociological status, and also the International Prostate Symptom Score (IPSS) with additional questions on discomfort related to urinary symptoms. Results: The response rate was 81.5%. Prevalence of mild and severe IPSS was 89.2%. Specific bother for each urinary symptom depended on symptom frequency: urgency, frequency, weak stream, nocturia, incomplete emptying, intermittency and straining 1 time out of 5 were responsible for discomfort in respectively 4.9, 6.1, 7.1, 7.5, 8.7 and 9.9%; the same symptoms more than half of the time were responsible for discomfort in respectively 32.8, 38, 45.3, 45.6, 53.2 and 58.7%. Urgency was much more deeply implicated in discomfort than frequency of nocturia. Conclusions: Urinary symptoms in men are very common. Nocturia is the most frequent but has a low impact on discomfort. Urgency has a higher impact on discomfort and should therefore be considered in treatment decision-making.


Journal of Endourology | 2010

Blood Loss During Transurethral Resection of the Prostate as Measured by the Chromium-51 Method

Aurélien Descazeaud; Abdel Rahmene Azzousi; Charles Ballereau; F. Bruyère; Grégoire Robert; N.B. Delongchamps; Marian Devonec; O. Dumonceau; Marc Fourmarier; Christian Saussine; Julien Berger; Alexandre de la Taille; O. Haillot

PURPOSEnTo evaluate blood loss during transurethral resection of the prostate (TURP), and its predictive factors, using the chromium 51 (51Cr) labeling method.nnnPATIENTS AND METHODSnFrom January to June 2008, 41 patients who underwent TURP for symptomatic benign prostatic hyperplasia (BPH) at four French urology centers were included in the analysis. Red cells volume was measured by the 51Cr method 1 day before TURP, and on postoperative day 3. Overall blood loss was estimated by multiplication of red cells volume loss and preoperative venous hematocrit value.nnnRESULTSnMean preoperative red cells volume was 1997 mL. Mean loss of red cells volume was 209 ml, which corresponds to an estimated blood loss of 507 mL. Mean delta of hematocrit and hemoglobin were 1.4% and 0.71 g/dL, respectively. In univariate analysis, prostate volume, weight of resected tissue, preoperative red cells volume, and resection time were significantly and directly associated with loss of red cells volume (P = 0.038, P = 0.004, P = 0.002, and P = 0.039, respectively). Bipolar and monopolar TURP did not lead to significant difference of red cells loss. In multivariate analysis, both preoperative red cells volume and weight of resected tissue were independent predictors of red cells loss (P = 0.017 and P = 0.048 respectively).nnnCONCLUSIONnWe present the first study to measure blood loss secondary to TURP using the 51Cr method. This technique allowed evaluating blood loss not only during the surgical procedure but also during the postoperative period. We learned from this study that, on average, blood loss from the procedure until postoperative day 3 was more than 500 mL, which is larger than previously reported amounts as measured by other methods. Because significant blood loss might occur during the postoperative period, the 51Cr method should be used to measure blood loss when evaluating new emerging techniques to manage BPH.


Progres En Urologie | 2014

Traitement de l’incontinence urinaire masculine non neurologique par hyperactivité vésicale : une revue de la littérature du CTMH de l’AFU

Souhil Lebdai; O. Haillot; A.R. Azzouzi; A. Benchikh; A. Campeggi; J.-N. Cornu; N.B. Delongchamps; O. Dumonceau; A. Faix; M. Fourmarier; Bertrand Lukacs; Romain Mathieu; V. Misrai; G. Robert; A. De La Taille; A. Descazeaud

PURPOSEnTo perform an update on the treatment of masculine urinary incontinence due to idiopathic overactive bladder.nnnMETHODnA systematic review was conducted using PubMed/MEDLINE with the following keywords: overactive bladder, male urinary incontinence, urgency, antimuscarinic, onabotulinumtoxinA, neurostimulation, cystoplasty.nnnRESULTSnAntimuscarinic treatments were the first line option for overactive bladder incontinence (decreased incontinence under tolterodine versus placebo respectively -71% vs. -40%, P < 0.05). Their main side effects were dry mouth (16-29.6%) and constipation (4%), which might decrease the observance. In case of failure, neuromostimulation could be prosed with a 67% efficacy rate. Intra-detrusorian injections of onabotulinumtoxinA were an option, however there were still not validated for this indication and their efficacy decreases with time and after repeated injections. The ultimate option in case of refractory major over-activity was cystoplasty, which involves major morbidity for inconstant efficacy.nnnCONCLUSIONSnThe same treatments are available for non-neurologic urinary incontinence by bladder over-activity for men and women: antimuscarinic drugs, neurostimulation, onabotulinumtoxinA. However, only few data is available for masculine population exclusively.


Progres En Urologie | 2017

Perioperative and economic analysis of surgical treatments for benign prostatic hyperplasia: A study of the French committee on LUT

Romain Mathieu; Souhil Lebdai; J.-N. Cornu; A. Benchikh; A.R. Azzouzi; N.B. Delongchamps; O. Dumonceau; A. Faix; M. Fourmarier; O. Haillot; Bertrand Lukacs; V. Misrai; A. De La Taille; G. Robert; A. Descazeaud

PURPOSEnTo evaluate perioperative cost related to surgical treatments of benign prostatic obstruction (BPO): photoselective vaporization of the prostate (pvp), holmium/thullium laser enucleation (HoLEP/ThuLEP), transurethral resection of the prostate (TURP) and open prostatectomy (OP).nnnMATERIAL AND METHODSnWe retrospectively collected data from 237xa0patients who consecutively underwent a surgical treatment for BPH between January 2012 and June 2013 at nine institutions in France. An economic simulation model was constructed to estimate the cost of hospitalization related to surgical procedure from the hospital perspective and a cost minimization analysis was performed.nnnRESULTSnTURP, OP, HoLEP/ThuLEP and PVP were performed in 99 (42%), 23 (10%), 64 (27%) and 51 (21%) patients, respectively. For men with prostate size<80mL: mean operative time was shorter with mTURP and PVP than HoLEP/thuLEP (P<0.001); Mean postoperative length of stay were 1.9, 3 vs. 3.4xa0days, for HoLEP/Thulep, PVP and TURP respectively (P=0.006); Costs of first hospitalization were comparable between HoLEP/ThuLEP and TURP but higher with PVP (P<0.001). For men with prostate size≥80mL: Compared to PVP and HoLEP/ThuLEP, OP was associated with shorter operative time (P<0.001) but longer length of stay (2.4, 4.2 vs. 7.8xa0days, respectively, P<0.0001); Costs of first hospitalization were significantly higher with OP than HoLEP/ThuLEP or PVP (P<0.001).nnnCONCLUSIONSnPVP and HoLEP/ThuLEP were associated with a shorter LOS than TURP and OP. This benefit suggests these procedures could be more cost effective than OP, but still not cheaper alternatives to TURP.nnnLEVEL OF EVIDENCEn5.


Progres En Urologie | 2016

Impact pronostique du genre féminin sur le devenir oncologique des patients traités par cystectomie totale

Y. Dabi; Y. Rouscoff; N.B. Delongchamps; Mathilde Sibony; D. Saighi; M. Zerbib; M. Peyraumore; Evanguelos Xylinas

OBJECTIVEnTo confirm gender specific differences in pathologic factors and survival rates of urothelial bladder cancer patients treated with radical cystectomy.nnnPATIENTS AND METHODSnWe conducted a retrospective monocentric study on 701 patients treated with radical cystectomy and pelvic lymphadenectomy for muscle invasive bladder cancer. Impact of gender on recurrence rate, specific and non-specific mortality rate were evaluated using Cox regression models in univariate and multivariate analysis.nnnRESULTSnWe collected data on 553 males (78.9%) and 148 females (21.1%) between 1998 and 2011. Both groups were comparable at inclusion regarding age, pathologic stage, nodal status and lymphovascular invasion. Mean follow-up time was 45 months (interquartile 23-73) and by that time, 163 patients (23.3%) had recurrence of their tumor and 127 (18.1%) died from their disease. In multivariable Cox regression analyses, female gender was independently associated with disease recurrence (RR: 1.73; 95% CI 1.22-2.47; P=0.02) and cancer-specific mortality (RR=2.50, 95% CI=1.71-3.68; P<0.001).nnnCONCLUSIONnWe confirmed female gender to be an independent negative prognosis factor for patients following a radical cystectomy and lymphadenectomy for an invasive muscle bladder cancer.


Progres En Urologie | 2014

Traitements palliatifs et conservateurs de l’incontinence urinaire masculine non neurologique : une revue de littérature du CTMH de l’AFU

Souhil Lebdai; N.B. Delongchamps; A.R. Azzouzi; A. Benchikh; A. Campeggi; J.-N. Cornu; O. Dumonceau; A. Faix; M. Fourmarier; O. Haillot; Bertrand Lukacs; Romain Mathieu; V. Misrai; G. Robert; A. De La Taille; A. Descazeaud

PURPOSEnTo perform an update on the conservative treatment of male non-neurologic urinary incontinence.nnnMETHODnA systematic review was conducted using PubMed/MEDLINE with the following keywords: incontinence, male stress urinary incontinence, pelvic floor training, biofeedback, absorbant products, life style, penile clamp.nnnRESULTSnPalliative devices like penile clamps, penile sheaths and absorbent products were transitory options that were poorly evaluated. Life style modifications (scheduled voiding, controlled hydric absorption, decreased caffeine and spice intake) were useful in complement of other treatments especially in case of overactive bladder. Pelvic floor training (PFT) was useful after radical prostatectomy but remained optional for other types of incontinence. It accelerated the continence recovery postoperatively but it results at 1 year were uncertain. These results were maintained 1 year. Conservative treatments were useful postoperatively especially early supervised PFT. The benefit of biofeedback and perineal stimulation was controversial. Balder catheterization was a last resort option. Penile sheaths were better than urethral catheterization if there were no post-voiding residual urines.nnnCONCLUSIONSnPalliative options have a limited efficacy but are mini-invasive and might be helpful complementary options.


Progres En Urologie | 2012

Traitement de l’hyperplasie bénigne de prostate par techniques endoscopiques électriques et adénomectomie voie haute : revue de littérature du CTMH de l’AFU

N.B. Delongchamps; G. Robert; A. Descazeaud; J.-N. Cornu; A.R. Azzouzi; O. Haillot; Marian Devonec; M. Fourmarier; Charles Ballereau; Bertrand Lukacs; O. Dumonceau; C. Saussine; A. De La Taille

Collaboration


Dive into the N.B. Delongchamps's collaboration.

Top Co-Authors

Avatar

O. Haillot

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Robert

Université Bordeaux Segalen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A.R. Azzouzi

University of Sheffield

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marian Devonec

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge